About the Company
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MNTA News
Johnson & Johnson to Buy Momenta Pharmaceuticals for $6.5 Billion
J&J will buy Momenta Pharmaceuticals for roughly $6.5 billion in cash, paving the way for its Janssen unit to expand its efforts into autoimmune disease treatments. J&J will pay $52.50 for each ...
Momenta Rockets After Analysts Get Bullish on Biopharma's Newest Treatment
Momenta Pharmaceuticals (MNTA) soared Wednesday after a pair of analysts issued bullish reports on shares of the biopharma amid promising results for a new, multibillion-dollar therapy the company ...
Momenta Pharmaceuticals
NOTE: All lobbying expenditures on this page come from the Senate Office of Public Records. Data for the most recent year was downloaded on January 22, 2016. Feel free to distribute or cite this ...
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...
Elite Pharmaceuticals, Inc. (ELTP)
Elite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call Transcript February 15, 2024 Elite Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
INZY Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases.
NOVARTIS AG's Net Worth
NOVARTIS AG has an estimated net worth of $1.34 Billion. This is based on reported shares across multiple companies, which include Cellular Biomedicine Group, Inc., Poseida Therapeutics, Inc ...
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections ...
KalVista Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Actinium Pharmaceuticals Inc ATNM
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
EGRX Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care ...
Alnylam Pharmaceuticals Inc ALNY
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...